May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Photodynamic Therapy with Verteporfin for the Treatment of Corneal Neovascularization: Report of 25 Cases
Author Affiliations & Notes
  • A. Niño
    Cornea, ISSEMYM, Mexico, Mexico
  • J.C. De–La–Luz–Osnaya
    Cornea, ISSEMYM, Mexico, Mexico
  • R.M. Romero–Castro
    Cornea, ISSEMYM, Mexico, Mexico
  • G. Padilla–Aguilar
    Cornea, ISSEMYM, Mexico, Mexico
  • R. Naranjo–Tackman
    Cornea, Asociación Para Evitar la Ceguera en México, Mexico, Mexico
  • Footnotes
    Commercial Relationships  A. Niño, None; J.C. De–La–Luz–Osnaya, None; R.M. Romero–Castro, None; G. Padilla–Aguilar, None; R. Naranjo–Tackman, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1632. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Niño, J.C. De–La–Luz–Osnaya, R.M. Romero–Castro, G. Padilla–Aguilar, R. Naranjo–Tackman; Photodynamic Therapy with Verteporfin for the Treatment of Corneal Neovascularization: Report of 25 Cases . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1632.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine efficacy, safety, clinical and angiographic course of patients treated for corneal neovascularization with Photodynamic Therapy (PDT) with Verteporfin (Visudyne®, Novartis AG, Basel, Switzerland).

Methods: : Patients with corneal neovascularization of different etiologies were prospectively analyzed and followed with anterior segment pictures and fluorescein angiography (FA) to evaluate the effects of PDT with Verteporfin for corneal vessels regression, adverse effects and effect on visual acuity (VA). Informed consent was obtained from all subjects and evaluations were made at 1, 15, 30, 90 and 180 days after treatment. The usual dose for choroidal neovascular membranes was used, and the laser spot was applied for 83 seconds 15 minutes after infusion.

Results: : Six month VA had improved at least one line in 5 patients (18.51%), and remained the same in the other 22; none lost VA. Total thrombosis was achieved in 14 patients (51.8%), partial thrombosis (50 to 90% vessel thrombosis) was achieved in 9 patients (33.3%). Two patients achieving less than 50% thrombosis and affected visual axis had a second PDT session, achieving final total thrombosis as well. The remaining two patients (7.4%) had 4 affected quadrants, achieved absolutely no thrombosis. Any subsequent candidates of the same characteristics were excluded due to lack of effect. Permanent thrombosis was also inversely dependent on the number of quadrants affected. Lumbar pain was the only adverse event, encountered in 2 patients. No changes in IOP, inflammatory signs or loss of VA were observed.

Conclusions: : PDT with Verteporfin is an effective and safe viable option for the treatment of corneal neovascularization of different causes, with potential improvement of visual acuity or as preparation for penetrating keratoplasty without signs of toxicity.

Keywords: cornea: clinical science • photodynamic therapy • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×